+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Female Emergency Contraceptive Pill Market by Active Ingredient (Levonorgestrel, Mifepristone, Ulipristal Acetate), Distribution Channel (Over the Counter, Prescription), End User Age Group, Sales Channel, Dosage Form - Global Forecast 2025-2030- Product Image
Female Emergency Contraceptive Pill Market by Active Ingredient (Levonorgestrel, Mifepristone, Ulipristal Acetate), Distribution Channel (Over the Counter, Prescription), End User Age Group, Sales Channel, Dosage Form - Global Forecast 2025-2030- Product Image
New

Female Emergency Contraceptive Pill Market by Active Ingredient (Levonorgestrel, Mifepristone, Ulipristal Acetate), Distribution Channel (Over the Counter, Prescription), End User Age Group, Sales Channel, Dosage Form - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6125717
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The female emergency contraceptive pill represents a pivotal intervention in reproductive healthcare, offering a critical layer of protection when primary contraceptive measures fail or are unavailable. Over recent years, the landscape has evolved dramatically as heightened patient awareness, supportive advocacy, and expanding clinical guidelines have converged to prioritize access and reduce unintended pregnancies. Regulatory bodies have gradually harmonized approval pathways while refining safety protocols, fostering an environment where innovation can flourish. In parallel, advancements in pharmaceutical formulation have increased the precision of hormone delivery, improving both efficacy and tolerability for diverse patient populations.

Building on these developments, the strategic importance of understanding distribution mechanisms and user behaviors cannot be overstated. Healthcare providers and policymakers are increasingly collaborating to optimize inventory management, ensure equitable geographic coverage, and integrate digital channels for education and fulfillment. As these foundational elements take shape, the stage is set to explore the transformative shifts in how stakeholders engage with, manufacture, and distribute emergency contraception.

Evolving regulatory frameworks and consumer empowerment are driving seismic shifts across the emergency contraceptive pill ecosystem with lasting influence

Regulatory reforms have accelerated, with agencies adopting more streamlined review processes and clarifying labeling requirements to reassure both prescribers and patients. This evolution has been accompanied by the normalization of emergency contraception in public discourse, driven in part by digital platforms that disseminate evidence-based information and counter longstanding stigmas. Consequently, consumer empowerment has surged, as individuals become adept at navigating online resources, selecting appropriate formulations, and weighing risks and benefits without medical gatekeeping. Leading pharmaceutical companies have responded by enhancing transparency around clinical data and launching awareness campaigns that foreground patient autonomy.

These concurrent shifts have also prompted the rise of novel commercial models. Direct-to-consumer channels, including telehealth consultations linked to expedited delivery services, have emerged as viable alternatives to traditional brick-and-mortar outlets. Meanwhile, collaborations between public health agencies and private enterprises are refining reimbursement frameworks and co-branding educational initiatives. Together, these dynamics signal a structural reconfiguration of the emergency contraceptive ecosystem, laying the groundwork for new strategic imperatives.

In-depth exploration of how the 2025 United States tariff adjustments have reshaped global sourcing cost structures and supply continuity for emergency contraception

The introduction of heightened tariffs on imported pharmaceutical ingredients and finished products by the United States has had a pronounced ripple effect on the emergency contraceptive supply chain. Manufacturers and distributors have been compelled to revisit sourcing strategies, increasingly looking to domestic production and alternative trade agreements to mitigate cost pressures. In response, several producers have diversified their supplier base, engaging with manufacturers in low-tariff jurisdictions while renegotiating long-term contracts to secure stability in raw material procurement.

Concurrently, the tariff environment has spurred innovation in formulation optimization aimed at reducing active ingredient volumes without compromising efficacy. Such initiatives have allowed cost savings to be partially absorbed within research and development budgets, thereby shielding end-users from steep price escalations. Importantly, government and industry stakeholders have maintained dialogue to ensure that regulatory compliance remains rigorous even as supply chain resilience becomes a paramount concern. This recalibration underscores the adaptability of the emergency contraceptive industry in the face of shifting trade policy landscapes.

Granular segmentation analysis unlocking powerful insights across active ingredients age groups distribution pathways and varied dosage form preferences

A nuanced understanding of active ingredient dynamics reveals that levonorgestrel formulations, available in both 0.75 mg and 1.5 mg dosages, continue to dominate market preference due to their established safety profile and broad regulatory acceptance. Mifepristone, predominantly in its 10 mg strength, is gaining traction through targeted clinical advocacy and enhanced provider training, while ulipristal acetate at 30 mg is distinguishing itself through extended post-exposure windows and differentiated efficacy metrics. Distribution channels further stratify market behavior, as over-the-counter availability broadens access among spontaneous end users, whereas prescription pathways maintain a critical role in provider-guided patient education and follow-up interventions.

Age group segmentation exposes distinct demand curves, with the 20-24 cohort exhibiting the highest frequency of utilization, closely followed by the 25-29 group, while both the 15-19 and 30-34 brackets underscore the importance of targeted outreach programs. Sales channels reflect evolving consumer preferences: hospital pharmacies preserve trust among those seeking professional counsel, retail pharmacies offer broad convenience, and online pharmacies cater to anonymity and speed. Dosage form plays a complementary role, as tablets account for the majority of adoption, though gel presentations are carving out a niche among patients prioritizing ease of ingestion and reduced gastrointestinal side effects.

Comprehensive regional examination illuminating distinctive demand patterns competitive dynamics and strategic opportunities across Americas EMEA and Asia-Pacific markets

Americas exhibit a heterogeneous demand pattern driven by varying levels of policy support and public health funding. In North America, established guidelines and insurance coverage facilitate widespread over-the-counter adoption, while Latin American markets show burgeoning growth propelled by non-governmental outreach and digital education channels. Europe, Middle East & Africa feature a mosaic of regulatory attitudes, where Western European nations benefit from integrated healthcare systems and generous reimbursement, whereas emerging markets in Eastern Europe and parts of Sub-Saharan Africa grapple with supply chain constraints and inconsistent provider awareness.

In the Asia-Pacific region, a dual narrative unfolds: advanced economies like Australia and Japan leverage robust telemedicine frameworks and high public awareness, whereas rapidly urbanizing markets in Southeast Asia and India drive demand through grassroots advocacy and burgeoning e-commerce infrastructures. Regional trade agreements and localized manufacturing hubs further influence distribution efficacy, underscoring the strategic importance of adaptive regulatory engagement and investments in cold-chain logistics to ensure equitable access across each geography.

Critical evaluation of leading industry participants highlighting strategic partnerships innovation pipelines and competitive positioning within the emergency contraceptive sector

Industry participants have navigated a complex competitive landscape by forging strategic alliances, undertaking targeted M&A activity, and investing heavily in clinical differentiation. Leading innovators are channeling resources into extended-window formulations and exploring complementary product portfolios, including digital adherence tools and patient support programs. Partnerships between pharmaceutical developers and rapid delivery platforms have accelerated time-to-patient, while co-branding initiatives with professional medical associations have bolstered provider confidence and continued education.

Mid-tier and generic manufacturers are leveraging scale efficiencies to compete on price, often focusing on high-volume markets with streamlined regulatory requirements. These players are enhancing operational resilience through dual-sourcing agreements and automation integration, enabling them to respond swiftly to supply disruptions. Smaller niche innovators, meanwhile, are carving out specialized segments by addressing unmet needs-such as gel formulations designed for patients with specific tolerability profiles-thereby reinforcing the importance of product differentiation as a competitive lever.

Practical strategic recommendations empowering industry leaders to navigate regulatory complexity optimize distribution channels and enhance patient engagement effectiveness

Industry leaders should prioritize collaborative engagements with regulatory authorities to co-create clear labeling guidelines and evidence-based safety communications that resonate with diverse patient segments. Strengthening alliances with telehealth providers and digital pharmacies will unlock new channels for rapid fulfillment and real-time patient education. Investment in modular manufacturing facilities and flexible packaging capabilities will mitigate tariff-driven cost volatility and enhance supply chain agility during periods of geopolitical uncertainty.

To deepen market penetration, companies ought to develop adaptive marketing frameworks that segment communications by age group, emphasizing confidentiality and ease of access for younger users while underscoring clinical credibility for older cohorts. Additionally, implementing data-driven distribution strategies will optimize stock levels across hospital, retail, and online pharmacies, ensuring continuity of supply in high-demand areas. Finally, incorporating patient feedback loops and leveraging telemonitoring technologies can elevate adherence rates and reinforce brand trust in a competitive marketplace.

Robust multi-dimensional research methodology integrating primary interviews secondary data triangulation and rigorous quality control protocols for end-to-end market understanding

This research employs a rigorous multi-stage approach, beginning with an extensive review of regulatory filings, clinical trial registries, and relevant peer-reviewed publications. Primary data collection involved in-depth interviews with key opinion leaders, including obstetric-gynecology specialists, pharmacy directors, and supply chain executives, to capture nuanced perspectives on emerging trends and operational challenges. Secondary research encompassed analysis of published white papers, trade association reports, and publicly available import-export databases to validate trade flows and tariff impacts.

Data triangulation was conducted by cross-referencing qualitative insights with quantitative indicators, ensuring the accuracy of segmentation delineations and the integrity of competitive profiling. A dedicated quality control protocol, featuring peer reviews and data audits, underpinned each phase of the study. The methodology’s iterative framework allowed for continuous refinement of assumptions and alignment with real-world stakeholder feedback, thus delivering a comprehensive and actionable market understanding.

Concise synthesis of key findings illuminating industry strengths challenges and potential trajectories for stakeholders driving the future of emergency contraception access

The landscape of female emergency contraception is undergoing profound transformation driven by regulatory renewal, consumer empowerment, and supply chain recalibration. Innovations in formulation science, combined with adaptive distribution models and responsive tariff mitigation strategies, have collectively enhanced both access and affordability. Segmentation analysis reveals that distinct patient cohorts and distribution channels require tailored engagement approaches, while regional variances underscore the importance of localized strategies.

As industry participants adapt to evolving trade policies and embrace digital channels, strategic collaboration across the value chain will be paramount. The convergence of clinical innovation, operational excellence, and patient-centric outreach offers a compelling blueprint for sustainable growth. By internalizing these insights, stakeholders can navigate complexity with confidence and drive forward the mission of expanding safe and effective emergency contraceptive options worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Active Ingredient
    • Levonorgestrel
      • 0.75 Mg
      • 1.5 Mg
    • Mifepristone
      • 10 Mg
    • Ulipristal Acetate
      • 30 Mg
  • Distribution Channel
    • Over The Counter
    • Prescription
  • End User Age Group
    • 15-19
    • 20-24
    • 25-29
    • 30-34
    • 35+
  • Sales Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Dosage Form
    • Gel
    • Tablet
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Teva Pharmaceuticals USA, Inc.
  • HRA Pharma S.A.S.
  • Gedeon Richter Plc
  • Bayer AG
  • Cipla Limited
  • Lupin Limited
  • Dr. Reddy's Laboratories Limited
  • Viatris Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid expansion of telehealth services enabling same-day emergency contraceptive pill delivery
5.2. Surge in generic levonorgestrel emergency contraceptive launches intensifying price competition
5.3. Regulatory reforms in Europe enabling over-the-counter emergency contraceptive availability for minors
5.4. Growing influence of e-commerce platforms on consumer preference for discreet emergency contraceptive purchase
5.5. Integration of mobile health apps to provide personalized guidance on emergency contraceptive use timing
5.6. Emergence of ulipristal acetate generics shifting market share from branded ellaOne products
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Female Emergency Contraceptive Pill Market, by Active Ingredient
8.1. Introduction
8.2. Levonorgestrel
8.2.1. 0.75 Mg
8.2.2. 1.5 Mg
8.3. Mifepristone
8.3.1. 10 Mg
8.4. Ulipristal Acetate
8.4.1. 30 Mg
9. Female Emergency Contraceptive Pill Market, by Distribution Channel
9.1. Introduction
9.2. Over the Counter
9.3. Prescription
10. Female Emergency Contraceptive Pill Market, by End User Age Group
10.1. Introduction
10.2. 15-19
10.3. 20-24
10.4. 25-29
10.5. 30-34
10.6. 35+
11. Female Emergency Contraceptive Pill Market, by Sales Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Female Emergency Contraceptive Pill Market, by Dosage Form
12.1. Introduction
12.2. Gel
12.3. Tablet
13. Americas Female Emergency Contraceptive Pill Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Female Emergency Contraceptive Pill Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Female Emergency Contraceptive Pill Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Teva Pharmaceuticals USA, Inc.
16.3.2. HRA Pharma S.A.S.
16.3.3. Gedeon Richter Plc
16.3.4. Bayer AG
16.3.5. Cipla Limited
16.3.6. Lupin Limited
16.3.7. Dr. Reddy's Laboratories Limited
16.3.8. Viatris Inc.
16.3.9. Pfizer Inc.
16.3.10. Sun Pharmaceutical Industries Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2030 (%)
FIGURE 6. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET: RESEARCHAI
FIGURE 26. FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET: RESEARCHSTATISTICS
FIGURE 27. FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET: RESEARCHCONTACTS
FIGURE 28. FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 0.75 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 0.75 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 1.5 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 1.5 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 10 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 10 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 30 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 30 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 15-19, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 15-19, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 20-24, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 20-24, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 25-29, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 25-29, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 30-34, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 30-34, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 35+, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 35+, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 100. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 101. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 102. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 103. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 104. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 105. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 106. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 107. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 110. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 111. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 114. CANADA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 115. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 116. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 117. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 118. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 119. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 122. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 123. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 126. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 127. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 130. MEXICO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 197. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 198. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 199. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 200. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 201. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 202. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 203. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 204. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 205. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 208. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 209. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 212. GERMANY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 213. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 214. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 215. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 216. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 217. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 218. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 219. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 220. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 221. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 224. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 225. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 228. FRANCE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 245. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 246. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 247. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 248. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 249. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 250. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 251. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 252. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 253. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 256. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 257. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 260. ITALY FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 261. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 262. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 263. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 264. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 265. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 266. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 267. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 268. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 269. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 272. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2025-2030 (USD MILLION)
TABLE 273. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 276. SPAIN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER AGE GROUP, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES FEMALE EMERGENCY CONTRACEPTIVE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Female Emergency Contraceptive Pill market report include:
  • Teva Pharmaceuticals USA, Inc.
  • HRA Pharma S.A.S.
  • Gedeon Richter Plc
  • Bayer AG
  • Cipla Limited
  • Lupin Limited
  • Dr. Reddy's Laboratories Limited
  • Viatris Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited

Related Topics

Related Reports

Emergency Contraceptive Pills Market by Product Type (Levonorgestrel, Mifepristone, Ulipristal Acetate), Prescription Type (Over The Counter, Prescription), Age Group - Global Forecast 2025-2030 - Product Image

Emergency Contraceptive Pills Market by Product Type (Levonorgestrel, Mifepristone, Ulipristal Acetate), Prescription Type (Over The Counter, Prescription), Age Group - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Contraceptive Market by Type (Emergency Contraceptives, Hormonal, Non-Hormonal), Formulation (Patch, Pill, Ring), Mode Of Action, Material Type, Duration, Usage Frequency, Sales Channel, Application, End-User - Global Forecast 2025-2030 - Product Image

Contraceptive Market by Type (Emergency Contraceptives, Hormonal, Non-Hormonal), Formulation (Patch, Pill, Ring), Mode Of Action, Material Type, Duration, Usage Frequency, Sales Channel, Application, End-User - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Emergency Contraceptive Pills Market 2025-2033 - Product Image

Emergency Contraceptive Pills Market 2025-2033

  • Report
  • 142 Pages
  • Global
From
North America Contraceptive Market Outlook, 2030 - Product Image

North America Contraceptive Market Outlook, 2030

  • Report
  • 90 Pages
  • North America
From
Female Contraceptive - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Female Contraceptive - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 112 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.